uniQure price target raised to $80 from $47 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on uniQure (QURE) to $80 from $47 and keeps an Overweight rating on the shares following the AMT-130 three-year topline data in Huntington’s disease. While there will be patients who take a wait-and-see approach pending AMT-130 approval, there is a lot of excitement in the patient advocacy community, the analyst tells investors in a research note. Cantor believes the three-year data could support approval and uptake. It increased its probability of success for AMT-130 in the U.S. to 75% from 45% and Europe to 45% from 15%.